Volume 29, Number 7—July 2023
CME ACTIVITY - Research
Clinical and Mycologic Characteristics of Emerging Mucormycosis Agent Rhizopus homothallicus
Shivaprakash M. Rudramurthy1, Shreya Singh12, Rimjhim Kanaujia, Hansraj Chaudhary3, Valliappan Muthu, Naresh Panda, Abhishek Pandey, Sheetal Thakur, Harsimran Kaur, Anup Ghosh, Ritesh Agarwal, and Arunaloke Chakrabarti4
Table 4
Distribution of MICs of 34 Rhizopus homothallicus isolates from patients enrolled in a 10-month retrospective study, Chandigarh, India, January–October 2021*
| Antifungal agent | Geometric mean (range), mg/L | MIC50, mg/L | MIC90, mg/L |
|---|---|---|---|
| Amphotericin B | 0.75 (0.03–16) | 2 | 4 |
| Itraconazole | 0.51 (0.03–16) | 0.5 | 8 |
| Posaconazole | 0.24 (0.03–8) | 0.12 | 2 |
| Isavuconazole | 0.32 (0.03–16) | 0.25 | 2 |
| Terbinafine | 0.34 (0.03–16) | 0.25 | 4 |
*MIC50, MIC at which 50% of isolates are inhibited; MIC90, MIC at which 90% of isolates are inhibited.
1These first authors contributed equally to this article.
2Current affiliation: Dr. B R Ambedkar State Institute of Medical Sciences, Mohali, India.
3Current affiliation: Indian Council of Medical Research, New Delhi, India.
4Current affiliation: Doodhadhari Burfani Hospital, Haridwar, India.
Page created: April 20, 2023
Page updated: June 20, 2023
Page reviewed: June 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.